// App-Quantinova.ai

: World Canadian Cohort of Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone

Researchers

Presenter

  • C. Ryerson

Principal Investigators

  • M. R. J. Kolb

  • G. P. Cox

  • S. Shapera

  • J. J. Swigris

  • C. D. Fell

  • M. O'Brien

  • M. Yang

  • C. Cabalteja

  • O. Moran Mendoza

Medical Centers

  • Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

  • McMaster University, Hamilton, ON, Canada

  • Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada,

  • University of Toronto, Toronto, ON, Canada

  • Interstitial Lung Disease Program, National Jewish Health, Denver, CO, United States,

  • Internal Medicine, University of Calgary, Calgary, AB, Canada

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Genentech Inc., San Francisco, United States

  • Pediatrics, Queens University, Kingston, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved